Genevieve M. Boland, MD, PhD (she/her/hers)

Vice Chair of Research, Section Head Melanoma/Sarcoma Surgery
Massachusetts General Hospital

Genevieve M. Boland, MD, PhD, FACS is an Associate Professor of Surgery at Harvard Medical School, Vice Chair of Research for the Department of Surgery, Section Head of Melanoma/Sarcoma Surgery, and Surgical Director of the Termeer Center for Targeted Therapies at the Massachusetts General Hospital. Her primary clinical focus is on melanoma and cutaneous oncology.

Presentation(s):

• The Use of Circulating Tumor DNA in the Management of Cutaneous, Thoracic and Breast Malignancies

  Thursday, March 23, 2023
  2:15 PM – 3:15 PM

  Disclosure(s): Ankyra Therapeutics: Advisor (Ongoing), Consultant (Ongoing), Stocks (Ongoing); InterVenn Bioscience: Advisor (Terminated, November 4, 2022), Consultant (Terminated, November 4, 2022), Research Grant (Terminated, November 4, 2022); Iovance Biotherapeutics: Advisor (Ongoing); Merck: Advisor (Ongoing), Consultant (Ongoing); Nektar Therapeutics: Advisor (Terminated, July 1, 2021); Novartis: Advisor (Terminated, November 4, 2022); Olink Proteomics: Research Grant (Ongoing); Palleon Pharmaceuticals: Research Grant (Terminated, November 4, 2022); Teiko Bio: Research Grant (Ongoing)

• Melanoma in Pregnancy - Immunotherapy Considerations

  Friday, March 24, 2023
  12:11 PM – 12:21 PM

  Disclosure(s): Ankyra Therapeutics: Advisor (Ongoing), Consultant (Ongoing), Stocks (Ongoing); InterVenn Bioscience: Advisor (Terminated, November 4, 2022), Consultant (Terminated, November 4, 2022), Research Grant (Terminated, November 4, 2022); Iovance Biotherapeutics: Advisor (Ongoing); Merck: Advisor (Ongoing), Consultant (Ongoing); Nektar Therapeutics: Advisor (Terminated, July 1, 2021); Novartis: Advisor (Terminated, November 4, 2022); Olink Proteomics: Research Grant (Ongoing); Palleon Pharmaceuticals: Research Grant (Terminated, November 4, 2022); Teiko Bio: Research Grant (Ongoing)

• P48: Increased Frequency of Gene Mutations Significantly Decreases Recurrence Risk In High-Risk Stage II Melanoma Patients.

  Friday, March 24, 2023
  3:31 PM – 3:36 PM

  Disclosure(s): Ankyra Therapeutics: Advisor (Ongoing), Consultant (Ongoing), Stocks (Ongoing); InterVenn Bioscience: Advisor (Terminated, November 4, 2022), Consultant (Terminated, November 4, 2022), Research Grant (Terminated, November 4, 2022); Iovance Biotherapeutics: Advisor (Ongoing); Merck: Advisor (Ongoing), Consultant (Ongoing); Nektar Therapeutics: Advisor (Terminated, July 1, 2021); Novartis: Advisor (Terminated, November 4, 2022); Olink Proteomics: Research Grant (Ongoing); Palleon Pharmaceuticals: Research Grant (Terminated, November 4, 2022); Teiko Bio: Research Grant (Ongoing)